Brokerages Set Sensus Healthcare, Inc. (NASDAQ:SRTS) Price Target at $5.83

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) have been given an average rating of “Moderate Buy” by the six research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $5.8333.

Several equities research analysts have recently weighed in on the company. Alliance Global Partners reaffirmed a “buy” rating on shares of Sensus Healthcare in a research report on Monday, August 17th. Weiss Ratings lowered Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Lake Street Capital decreased their price target on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a report on Friday, August 14th. Wall Street Zen downgraded shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Finally, Citigroup reissued a “buy” rating on shares of Sensus Healthcare in a research report on Friday, May 8th.

Sensus Healthcare Price Performance

Sensus Healthcare stock opened at $3.52 on Monday. The firm has a fifty day moving average of $3.05 and a 200-day moving average of $3.51. Sensus Healthcare has a 52-week low of $2.66 and a 52-week high of $5.49. The firm has a market capitalization of $57.94 million, a P/E ratio of -3.74 and a beta of 1.10.

Sensus Healthcare (NASDAQ:SRTS) last posted its earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.41). Sensus Healthcare had a negative net margin of 88.45% and a negative return on equity of 21.57%. The business had revenue of $2.29 million for the quarter, compared to analyst estimates of $4.60 million.

Insider Buying and Selling

In other news, Director Eric Sachetta acquired 34,697 shares of the firm’s stock in a transaction on Monday, August 24th. The stock was bought at an average cost of $3.25 per share, with a total value of $112,765.25. Following the transaction, the director directly owned 209,310 shares in the company, valued at approximately $680,257.50. This represents a 19.87% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last quarter, insiders have acquired 55,330 shares of company stock valued at $179,446. Insiders own 10.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of SRTS. EP Wealth Advisors LLC acquired a new stake in Sensus Healthcare during the 2nd quarter valued at approximately $49,000. XTX Topco Ltd acquired a new position in shares of Sensus Healthcare in the 4th quarter valued at approximately $77,000. Jane Street Group LLC purchased a new position in shares of Sensus Healthcare during the 4th quarter valued at approximately $79,000. Ingalls & Snyder LLC purchased a new position in shares of Sensus Healthcare during the 4th quarter valued at approximately $219,000. Finally, State Street Corp grew its position in shares of Sensus Healthcare by 5.2% during the fourth quarter. State Street Corp now owns 69,252 shares of the company’s stock worth $276,000 after buying an additional 3,400 shares in the last quarter. Institutional investors and hedge funds own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.